Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that it repurchased 70,000 H shares on 30 September 2026 via on-exchange transactions at prices ranging between HKD 3.27 and HKD 3.33, for a total consideration of HKD 0.23 million. The volume-weighted average purchase price was HKD 3.3184 per share.

Following the transaction, Weigao Group’s issued share capital (excluding treasury shares) declined from 4.46 billion to 4.46 billion shares, representing a marginal reduction of 0.0016%. Concurrently, the company’s treasury-share holding rose to 66.22 million shares, while total issued shares remained unchanged at 4.52 billion.

The buyback formed part of the repurchase mandate approved on 29 May 2026, which authorises the company to repurchase up to 446.46 million shares. To date, Weigao Group has repurchased 8.89 million shares under this mandate, equivalent to 1.99% of the issuer’s outstanding shares on the approval date.

In accordance with Hong Kong Stock Exchange rules, Weigao Group is subject to a moratorium on new share issues or sales of treasury shares until 31 October 2026. The company confirmed that all repurchase activities complied with applicable regulations and that no repurchased shares have been cancelled to date, as the 70,000 shares will be retained as treasury stock.